HOOKOTCPharmaceutical PreparationsUS GAAP · USD

HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing immunotherapies and vaccine candidates built on its proprietary replicating and non-replicating viral vector technologies. The company has not commercialized any products and currently generates revenue only from collaboration and licensing agreements, primarily with Gilead and Roche.

Kysy yhtiöstä
Liikevaihto43,9milj. USD
+118,3 %v/v
Liikevoitto (EBIT)−51,5milj. USD
+47,3 %v/v
EBIT-marginaali−117,1%
+368,3 %-yks.v/v
Nettotulos−43,5milj. USD
+46,7 %v/v
Vapaa kassavirta−77,2milj. USD
−25,1 %v/v

Tilikausi 2024 · muutos edellisvuodesta

Kehitys 2019–2024

−100−50050milj. USD2019: 12 milj. USD2019: EBIT −51 milj. USD20192020: 5,2 milj. USD2020: EBIT −53 milj. USD20202021: 18 milj. USD2021: EBIT −82 milj. USD20212022: 14 milj. USD2022: EBIT −73 milj. USD20222023: 20 milj. USD2023: EBIT −98 milj. USD20232024: 44 milj. USD2024: EBIT −51 milj. USD202444−51
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: HOOKIPA Pharma Inc.

Liiketoiminta

Osuus liikevaihdosta
Vaccine and immunotherapy candidates0 %

Preclinical and clinical product candidates designed to prevent or treat serious diseases using viral-vector-based immunology.

Technology platforms0 %

Replicating and non-replicating viral vector technologies used to create new product candidates and partnership opportunities.

Collaboration and licensing revenue100 %

Upfront, milestone, initiation and reimbursement revenue from partner agreements such as Gilead and Roche.

Asiakkaat

HOOKIPA does not sell commercial products today; its customers are collaboration partners that fund research and development through licensing and development agreements. The company’s end-market focus is on patients with HBV, HIV, cancer and other serious diseases, but monetization currently comes from large pharmaceutical partners rather than direct product sales.

Pharmaceutical collaboration partners

Large biopharma companies that pay upfront, milestone and reimbursement amounts to access HOOKIPA’s technology and programs.

Government and grant funding sources

Public-sector programs that provide research incentives and non-dilutive funding to support development work.

Future patients and healthcare providers

Patients and clinicians in HBV, HIV, oncology and other serious-disease areas that would use approved products if development succeeds.

Strategia

The company’s near-term strategy is to advance current and future product candidates through preclinical and clinical development while seeking regulatory approvals where data support them. It also aims to secure additional financing and collaborations, build manufacturing access through third parties, and eventually create the commercial infrastructure needed for any approved products.

Advance clinical and preclinical programsLyhyt aikaväli

Pipeline progress is the main value driver because the company has no product sales today.

Secure non-dilutive and dilutive fundingLyhyt aikaväli

The company expects continued losses and needs capital to avoid slowing or stopping development.

Strengthen manufacturing and commercialization readinessKeskipitkä aikaväli

Approved products would require reliable supply, quality control and a sales infrastructure.

Maantiede

HOOKIPA is headquartered in the United States but has meaningful operational exposure to Austria, where it references local macroeconomic conditions and received Austrian government research incentives. Its business is globally connected through collaboration partners, third-party suppliers and clinical development activities, so trade policy, tariffs and foreign exchange conditions can affect costs and timelines.

Riskit

HOOKIPA faces classic clinical-stage biotech risks: program failure, delayed trials, regulatory setbacks and the need for substantial additional capital. It also has material exposure to trade policy, third-party manufacturing dependence and macroeconomic conditions that can affect funding access, supply chains and development costs.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Third-party manufacturing dependence1Insufficient financing2Trade policy and tariff exposure5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Third-party manufacturing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    HOOKIPA does not own or operate manufacturing facilities and relies on external suppliers and manufacturers.

    KohdistuuSupply interruptionsQuality issuesScale-up delays
  2. Insufficient financingVaikutus: KorkeaTodennäköisyys: Matala

    The company expects continued losses and says it will require substantial additional capital to continue programs.

    KohdistuuCould force delaysReductions or termination of development activities
  3. Clinical and regulatory failureVaikutus: Korkea

    Product candidates must succeed in preclinical studies, clinical trials and regulatory review before any product revenue can begin.

    Kohdistuu: Pipeline value and future commercialization depend on trial outcomes

  4. Collaboration concentrationVaikutus: Korkea

    Current revenue is concentrated in a small number of collaboration agreements, so termination or non-renewal would materially reduce revenue.

    Kohdistuu: Gilead and Roche collaboration revenue

  5. Trade policy and tariff exposureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The company relies on a global supply chain and notes that tariffs and trade barriers could increase costs and delay development.

    Kohdistuu: Suppliers outside the United States and imported research materials

Kysy Clarifolta: HOOKIPA Pharma Inc.

Kirjanpito

Harkinnanvaraiset erät
Collaboration revenue recognition

Revenue includes upfront, milestone and initiation payments recognized as deferred revenue is released or milestones are achieved.

Vaikutus: Can create large quarter-to-quarter swings in revenue and earnings

Deferred revenue

Termination or acceleration of collaboration arrangements can cause early recognition of deferred amounts.

Vaikutus: Material effect on reported revenue and operating cash flow timing

Research incentives and receivables

The company recorded receivable research incentives, including Austrian government research incentive amounts.

Vaikutus: Affects working capital and cash conversion

Estimates and judgments

Management states that financial statements require ongoing estimates and assumptions under GAAP.

Vaikutus: Can affect asset, liability and expense recognition

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Bicara Therapeutics Inc.

BCAX · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

GT Biopharma, Inc.

GTBP · Pharmaceutical Preparations

Vir Biotechnology, Inc.

VIR · Biological Products, (No Diagnostic Substances)

Cocrystal Pharma, Inc.

COCP · Pharmaceutical Preparations

Caribou Biosciences, Inc.

CRBU · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026

HOOKIPA Pharma Inc. (OTC) – Pharmaceutical Preparations | Analyysi – Clarifo